Physician profile
Abdul Wahab
NPI 1043230980
$35,628.46
in general payments reported to CMS, 2019-2025
41 companies · $880 in 2025
The $880 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $4,309 · 2021: $1,105 · 2022: $1,551 · 2023: $1,564 · 2024: $1,265 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,479 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,478.62 |
| Education | $230.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28,239.20 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $836.12 | 2020-2024 | Acthar |
| Astrazeneca Pharmaceuticals LP | $707.52 | 2019-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $682.77 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $661.01 | 2019-2025 | Trelegy Ellipta, Benlysta, Arexvy |
| Ani Pharmaceuticals, INC. | $624.43 | 2022-2024 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $434.35 | 2019-2023 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $339.32 | 2019-2024 | Jynarque, Rexulti |
| Merck Sharp & Dohme LLC | $319.21 | 2022-2025 | Verquvo, Belsomra, Steglatro |
| Opko Pharmaceuticals, LLC | $266.78 | 2019-2023 | Rayaldee |
| Akebia Therapeutics INC | $241.54 | 2019-2025 | Vafseo, Auryxia |
| Ardelyx, INC. | $241.06 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $237.07 | 2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.88 | 2019-2025 | Jardiance |
| Amgen INC. | $191.73 | 2019-2025 | Otezla, Repatha, Repatha |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Wahab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.